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Introduction
MicroRNAs (miRNAs) are emerging as a new layer of regulators
of gene expression at the post-transcriptional level; approximately
22 nucleotides long, they generally inhibit translation or promote
mRNA degradation by base-pairing to complementary sequences
within the 3 untranslated regions (UTRs) of regulatory target
mRNAs (Ambros, 2004; Bartel, 2004) (Fig. 1). Hundreds
of miRNAs have been identified and many of them are highly
conserved across a number of species, including plants, worms and
humans (Berezikov et al., 2006; Griffiths-Jones, 2004).
Bioinformatic analyses indicate that miRNAs might target more
than a third of human protein-coding genes (John et al., 2004; Lewis
et al., 2003). Individual messenger RNAs (mRNAs) can be targeted
by several miRNAs, and a single miRNA can regulate multiple target
mRNAs. More importantly, miRNAs can coordinately regulate a
set of genes encoding proteins with related functions, providing
enormous complexity and the potential of gene regulation (Esau
et al., 2006; Leung and Sharp, 2007).
The very first miRNA genes, lin-4 and let-7, were identified in
Caenorhabditis elegans by loss-of-function mutations that cause
strong defects in developmental timing (Lee et al., 1993; Reinhart
et al., 2000; Wightman et al., 1993). Additional genetic studies
performed in C. elegans and Drosophila melanogaster further
support the view that miRNAs have crucial roles in animal
development by fine-tuning, or acting as on-off switches in, gene
expression (Brennecke et al., 2003; Johnston and Hobert, 2003; Li
and Carthew, 2005). The genetic evidence for roles for specific
miRNAs in vertebrate development is accumulating slowly, largely
because vertebrate miRNAs exist as families with similar or even
identical sequences (Lagos-Quintana et al., 2002). However,
inducing the loss of all miRNAs in mice by depleting Dicer (also
known as Dicer1), a ribonuclease III enzyme responsible for
miRNA maturation, caused arrested development during
gastrulation before the body plan was fully configured (Bernstein
et al., 2003), suggesting that miRNAs are crucial for early vertebrate
development.
Interestingly, a subset of miRNAs are either specifically or highly
expressed in cardiac and skeletal muscle (Chen et al., 2006; Lagos-
Quintana et al., 2002; Wienholds et al., 2005), providing an
opportunity to understand how gene expression in these muscle
types is controlled at the post-transcriptional level by miRNAs.
Muscle cells have provided a powerful system for understanding
the genetic networks that control cell differentiation and
organogenesis. In this Commentary, we discuss the roles of miRNAs
in normal muscle development and function, and in muscle
disorders, and consider the prospects for therapeutically exploiting
muscle-miRNA biology.
Regulation of miRNA expression in cardiac and
skeletal muscle
Cardiac- and skeletal-muscle development begins when mesoderm
stem cells adopt muscle-specific fates in response to cues from
adjacent tissues (Buckingham, 2006; Solloway and Harvey, 2003).
Although both muscle types have distinct structural genes and
different functions, cardiac and skeletal muscle share a subset of
transcriptional factors and signals that control their specification
and differentiation (McKinsey et al., 2002; Potthoff and Olson,
2007). The MADS (MCM1, agamous, deficiens, serum response
factor)-box transcriptional factors, including SRF (serum
response factor) and MEF2 (myocyte enhancer factor 2), control
cardiac- and skeletal-muscle differentiation in combination with
other transcriptional regulators. SRF and MEF2 activate skeletal-
muscle-specific genes in combination with myogenic bHLH (basic
helix-loop-helix) factors, including MyoD and myogenin.
Differentiation of cardiac muscle is cooperatively controlled by
interactions between SRF and MEF2 together with GATA
transcription factors, the homeodomain protein Nkx2.5, the
transcriptional coactivator myocardin and others (Liu and Olson,
2006; Olson, 2002).
The regulation of muscle gene expression by the well-known
transcriptional networks involving SRF, MEF2 and other
transcription factors is complex (Niu et al., 2007). However, the
MicroRNAs (miRNAs) are a class of non-coding regulatory
RNAs of ~22 nucleotides in length. miRNAs are highly
conserved across a number of species, including plants, worms
and humans. miRNAs regulate gene expression post-
transcriptionally, primarily by associating with the 3
untranslated region (UTR) of their regulatory target mRNAs.
Recent work has begun to reveal roles for miRNAs in a wide
range of biological processes, including cell proliferation,
differentiation and apoptosis. miRNAs are expressed in cardiac
and skeletal muscle, and dysregulated miRNA expression has
been correlated with muscle-related disorders. Genetic studies
have identified distinct roles for specific miRNAs during
cardiogenesis, cardiac hypertrophy and electrical conduction.
Furthermore, conditionally inhibiting the maturation of
miRNAs in mouse cardiac and skeletal muscles has revealed
that miRNAs are essential for the development and function of
those muscles. These previously unrecognized regulators shed
new light on the molecular mechanisms that underlie muscle
development and pathology, and suggest the potential
importance of miRNAs as diagnostic markers and therapeutic
targets for muscle-related disease.
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discovery of miRNAs as a previously unrecognized component of
these networks starts to add an entirely new layer of complexity at
the post-transcriptional level to our understanding of how muscle
gene expression is regulated. SRF and MEF2 both regulate the
expression of two pairs of related muscle-specific miRNA genes:
miR-1-1 and miR-133a-2 (miR-1-1/miR-133a-2; clustered on
mouse chromosome 2), and miR-1-2 and miR-133a-1 (miR-1-2/
miR-133a-1; clustered on mouse chromosome 18). Each miRNA
pair is encoded by a bicistronic miRNA gene (Chen et al., 2006;
Liu et al., 2007; Niu et al., 2007; Rao et al., 2006; Zhao et al., 2005)
(Fig. 2). In skeletal muscle, SRF and MEF2 cooperate with MyoD
and myogenin to activate the expression of these miRNAs, the
upstream promoter and/or enhancers of which contain binding sites
for the SRF and MEF2 transcription factors. In the heart, SRF directs
the expression of these miRNAs in ventricular and atrial myocytes
(Niu et al., 2008), whereas MEF2 binds to the intronic enhancer of
these miRNA genes to activate their expression in ventricular
myocytes. A third pair of related miRNAs, miR-206 and miR-133b
(miR-206/miR-133b), are skeletal-muscle specific and are controlled
by MEF2, MyoD, myogenin and other regulators (Kim et al., 2006;
Rao et al., 2006; Rosenberg et al., 2006). miR-1-1 and miR-1-2 are
identical in nucleotide sequence, whereas miR-206 differs
from miR-1-1 and miR-1-2 by four nucleotides. miR-133a-1,
miR-133a-2 and miR-133b have the same sequence except for one
nucleotide at the 3 end of miR-133b (Fig. 2). The sequence
similarity of these muscle-specific miRNAs suggests that they share
the same or similar regulatory mRNA targets and creates a
substantial challenge to functionally study these miRNAs using
conventional loss-of-function approaches.
The primary transcripts of both miR-1-1/miR-133a-2 and
miR-206/miR-133b are derived from independent non-coding
RNAs, whereas the precursor of miR-1-2/miR-133a-1 is derived
from the intron of Mib1, an E3 ubiquitin ligase (Chen et al., 2006)
(Fig. 2). Considering the ubiquitous expression pattern of Mib1,
the muscle-specific expression of miR-1-2/miR-133a-1 must rely
on its own promoter. In contrast to the miR-1, miR-133 and miR-206
miRNAs, which are expressed as independent transcriptional units,
miR-208a is encoded by an intron of its host gene, α-myosin heavy
chain (Myh6; also known as αMHC). Both miR-208a and αMHC
are cardiac specific and are concurrently expressed during
development, suggesting that their expression levels are controlled
by a common regulatory element (van Rooij et al., 2007). In
addition, miR-208b (another member of the miR-208 miRNA
family), which shares a high level of sequence similarity with
miR-208a, is located within the intron of the gene encoding
β-myosin heavy chain (Myh7; also known as βMHC), whereas
miR-499 is located in the intron of its host myosin heavy chain 7b
(Myh7b) gene (Landgraf et al., 2007) (Fig. 2). Although their
expression and function have not yet been described, our
unpublished data show that miR-208b and miR-499 are 
co-expressed with their host myosin genes in cardiac muscle.
Collectively, the expression of muscle-specific miRNAs is under
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Fig. 1. miRNA gene regulatory networks and unique miRNA features.
(A) Control of gene expression involves transcriptional, miRNA-mediated
post-transcriptional and translational regulation. The selective expression of
primary miRNAs and regular messenger RNAs (mRNAs) starts at the
transcription step. mRNAs are further post-transcriptionally regulated by
miRNAs through base-pairing to complementary sequences within the 3
untranslated regions (UTRs) of the mRNAs, resulting in mRNA degradation
and/or translational repression. (B) Features of miRNAs. Large numbers of
miRNAs, which are highly conserved across species, have been identified and
many of them are abundantly expressed. A single miRNA is thought to have
dozens of targets and one particular mRNA can be regulated by multiple
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tight spatial and temporal regulation by transcriptional networks
that are important for muscle gene expression.
miRNAs in skeletal-muscle proliferation and
differentiation
The importance of miRNAs in normal skeletal-muscle development
is highlighted by Dicer loss-of-function studies (O’Rourke et al.,
2007). A conditional Dicer allele was specifically removed in the
skeletal muscle by the expression of Cre recombinase under
the control of MyoD regulatory elements, which direct gene
expression in skeletal muscle as early as embryonic day 9.5 (E9.5).
The elimination of Dicer in skeletal muscle disturbs embryonic and
postnatal skeletal-muscle development, causing skeletal-muscle
hypoplasia and perinatal death of mutant mice (O’Rourke et al.,
2007).
The proliferation and differentiation of skeletal-muscle cells is
mutually exclusive. The proliferating muscle cells (myoblasts)
actively expand under growth conditions, whereas they quickly exit
from the cell cycle in response to growth-factor depletion
(differentiation conditions) and fuse to form terminally differentiated
multinucleated myotubes (Parker et al., 2003; Pownall et al., 2002).
By regulating the balance between the antagonistic activity of cell
proliferation and differentiation, miRNAs are integral components
of genetic regulatory circuits for skeletal-muscle development. Our
laboratory reported that the muscle-specific miRNAs miR-1
and miR-133 modulate skeletal-muscle-cell proliferation and
differentiation by repressing the activity of HDAC4 (histone
deacetylase 4; a signal-dependent inhibitor of muscle differentiation)
and SRF, respectively, thereby establishing negative-feedback loops
for muscle-cell differentiation (Chen et al., 2006). Using a C2C12
myoblast model system, which faithfully mimics skeletal-muscle
development in vitro, overexpression and knockdown experiments
demonstrated that miR-1 enhances skeletal-muscle-cell
differentiation. In further support of those in vitro results, the
injection of single-cell Xenopus laevis embryos with miR-1 led to
developmental defects in which miR-1 promoted the differentiation
of muscle cells but inhibited their proliferation. Furthermore, miR-1
represses the expression of HDAC4, which represses MEF2 activity
(Lu et al., 2000; McKinsey et al., 2000). MEF2, in turn, is a potent
activator of miR-1 expression in skeletal and cardiac muscle (Liu
et al., 2007; Rao et al., 2006). Therefore, the upregulation of miR-1
during skeletal-muscle development is an effective mechanism to
dampen the expression of HDAC4 and promote muscle-cell
differentiation through the activity of MEF2 (Fig. 3).
By contrast, miR-133 promotes the proliferation of myoblasts
and inhibits their differentiation. miR-133 enhances myocyte
proliferation, at least in part, by reducing protein levels of SRF, a
crucial regulator of muscle-cell differentiation (Chen et al., 2006;
Niu et al., 2007). miR-133 also inhibits the translation of
polypyrimidine tract-binding protein (nPTB), which controls
differential transcript splicing during skeletal-muscle-cell
differentiation (Boutz et al., 2007). Paradoxically, miR-1 and 
miR-133 exert opposing effects on skeletal-muscle development
despite originating from the same miRNA polycistronic transcript.
Interestingly, miR-1 and miR-133 also produce opposing effects on
apoptosis (Xu et al., 2007). Additionally, embryonic stem (ES)-cell
differentiation towards cardiomyocytes is promoted by miR-1 and
inhibited by miR-133 (Ivey et al., 2008). These studies support the
view that miR-1 and miR-133 fine-tune key regulatory pathways
for muscle-cell proliferation and differentiation in an antagonistic
manner, with the balance being tipped one way or the other by
additional regulators of gene expression.
miR-1 is highly conserved among worms, flies, fish and humans.
Genetic studies in Drosophila revealed that miR-1-mutant larvae
exhibit decreased locomotion, which ultimately progresses to death,
accompanied by severe gross disruption of the larval musculature
(Kwon et al., 2005; Sokol and Ambros, 2005). A subset of severely
affected miR-1-null larvae exhibited an enlarged pool of cardiac
progenitors (Kwon et al., 2005), indicating that miR-1 inhibits cell
proliferation; this result is consistent with mammalian studies
involving miR-1.
Similar to miR-1 in skeletal muscle, miR-206, which is specific
to skeletal muscle and is not found in cardiac muscle, promotes
myoblast differentiation. miR-206 has been shown to inhibit the
expression of the gap-junction protein connexin 43 (Cx43), thereby
decreasing the electrical coupling between myofibers via gap
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Fig. 2. Genomic structures of muscle-specific miRNAs and their sequence homologies. (A) The genomic locations of muscle-specific miRNA genes, including
miR-1-1/miR-133a-2, miR-1-2/miR-133a-1, miR-206/miR-133b, miR-208a, miR-208b and miR-499, on mouse chromosomes. The expression of these miRNAs and
the host genes in which they reside are also indicated. (B) Comparison of muscle-specific miRNA sequences (shown 5-3). Matching colors indicate the homology












junctions, which impedes the terminal differentiation of skeletal-
muscle cells (Anderson et al., 2006). miR-206 also represses the
translation of the p180 subunit of DNA polymerase-α (polA1),
thereby inhibiting DNA synthesis and suppressing cell proliferation
(Kim et al., 2006). In addition, miR-206 has been proposed to be
the missing link that underlies MyoD-mediated gene repression
during skeletal-muscle-cell differentiation, in which miR-206
mediates the inhibition of the genes encoding follistatin-like 1 (Fstl1)
and utrophin (Utrn) in skeletal-muscle cells (Rosenberg et al., 2006).
In addition to muscle-specific miR-1, miR-133 and miR-206,
several other miRNAs have also been implicated in skeletal-
muscle-cell proliferation and differentiation. miR-181 is broadly
expressed and upregulated in response to skeletal-muscle injury
(Naguibneva et al., 2006). miR-181 is also upregulated during
myocyte differentiation and represses homeobox protein Hox-A11,
a repressor of muscle-cell differentiation, thereby allowing new
muscle growth (Naguibneva et al., 2006). miR-214 is expressed in
skeletal-muscle progenitor cells during zebrafish development and
was shown to specify the muscle-cell type by modulating the
response of muscle progenitor cells to Hedgehog signaling (Flynt
et al., 2007). It will be interesting to test whether miR-214 has a
similar role in mammalian skeletal-muscle development.
miRNAs in normal heart development
Two studies of heart-specific Dicer deletion illustrate that miRNAs
have crucial roles during normal vertebrate heart development and
function (Chen et al., 2008; Zhao et al., 2007). Conditional deletion
of Dicer, a protein that is required for miRNA maturation, removed
all cardiac-expressed miRNAs. The use of a Cre recombinase
controlled by the predominantly postnatally expressed αMHC
promoter to delete Dicer in the heart did not affect the specification
and patterning of cardiac muscle. However, the hearts of those mice
exhibited aberrant expression of cardiac contractile proteins and
remarkable sarcomere disarray coupled with significantly reduced
cardiac function; the mice progressed rapidly to dilated
cardiomyopathy, heart failure and postnatal death (Chen et al., 2008).
However, the use of Cre recombinase under the control of the Nkx2.5
promoter, which directs Cre recombinase expression in the early
embryonic heart, to delete Dicer resulted in early embryonic
lethality with heart morphogenesis defects in some Dicer-null
embryos (Zhao et al., 2007). Genetic elimination of Dicer at different
heart developmental stages has provided strong evidence that
miRNAs are required for normal heart development and function.
Genetic studies have also revealed crucial and distinct roles for
individual miRNAs in cardiac development (Chen et al., 2006; van
Rooij et al., 2006; van Rooij et al., 2007; Zhao et al., 2007). In
developing mouse embryos, overexpression of miR-1 in the heart
causes lethality during mid-embryogenesis owing to cardiomyocyte
deficiency and subsequent heart failure (Zhao et al., 2005), whereas
the introduction of miR-1 into developing Xenopus embryos also
perturbs heart development, with defects in cell proliferation (Chen
et al., 2006). Excessive numbers of cardiac cells were consistently
found in miR-1-2-knockout hearts (Zhao et al., 2007), indicating
that miR-1 inhibits cell proliferation during normal heart
development. Furthermore, forced expression of miR-1 promotes
ES-cell differentiation towards a cardiac lineage (Ivey et al., 2008).
Although definitive functions of miR-133 in heart development are
yet to be established, it is intriguing to speculate that miR-133 will
also have distinct roles in heart development, as miR-1 and 
miR-133 have opposing functions in skeletal muscle (Chen et al.,
2006). miR-208a is exclusively expressed in the heart but,
interestingly, its deletion in the mouse heart did not cause 
any apparent gross developmental defects, suggesting that 
miR-208a is not crucial for normal heart development (van 
Rooij et al., 2007). The reported phenotypes of other transgenic
mice that overexpress miRNAs range from benign to catastrophic: 
miR-214 overexpression led to no apparent cardiac defects, miR-
195 overexpression caused hypertrophic growth in the adult heart
and overexpression of miR-24 resulted in embryonic lethality (van
Rooij et al., 2006). Together, these findings indicate that miRNAs
are required for normal cardiogenesis, with individual 
miRNAs having specific roles.
miRNAs in skeletal-muscle disorders
Primary skeletal-muscle disorders involve different groups of
diseases, including muscular dystrophies, inflammatory myopathies
and congenital myopathies. Currently, although the number of genes
known to be involved in muscle disorders increases every year and
histological pathology of disease tissue is well documented, the
underlying molecular pathways remain poorly understood (Davies
and Nowak, 2006). Recent studies have begun to link miRNAs and
certain muscle-related diseases together (Eisenberg et al., 2007;
McCarthy and Esser, 2007; McCarthy et al., 2007).
miR-206 levels are elevated in the diaphragm muscle of the mdx
(also known as Dmd) mouse, an animal model of muscular
dystrophy (McCarthy et al., 2007). Moreover, the expression levels
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Fig. 3. Model of miR-1- and miR-133-mediated gene regulation during 
muscle proliferation and differentiation. Tissue-specific expression of miR-1
and miR-133 clusters is controlled by the transcription factors SRF, MEF2 and
MyoD. miR-1 promotes muscle differentiation by repressing the expression of
HDAC4 (histone deacetylase 4), a signal-dependent inhibitor of muscle
differentiation that represses MEF2 activity. MEF2, in turn, potently activates
the expression of myoblast-differentiation genes and miR-1. miR-133,
however, reduces protein levels of SRF, a crucial regulator of muscle
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of miR-1 and miR-133a were decreased in a mouse model of
skeletal-muscle hypertrophy (McCarthy and Esser, 2007).
Comprehensive miRNA expression-profiling studies revealed that
a total of 185 miRNAs were dysregulated in samples of diseased
muscle tissue from ten different muscle disorders – five miRNAs
(miR-146b, miR-221, miR-155, miR-214 and miR-222) were
consistently regulated in almost all samples that were examined
(Eisenberg et al., 2007), suggesting a possible involvement of
common miRNA-mediated regulatory mechanisms in muscle
disorders. In addition to those studies of miRNA expression in
muscle disorders, a direct genetic link has connected miRNA
function to muscle hypertrophy (Clop et al., 2006). A mutation that
is responsible for the exceptional muscularity of Texel sheep has
been mapped to a single G-to-A mutation within the 3 UTR of the
mRNA encoding myostatin, a member of the transforming growth
factor-β (TGFβ) family; myostatin functions to repress muscle
growth. This mutation creates a binding site for miR-1 and miR-206,
leading to the translational repression of myostatin, which
phenocopies the ‘muscle doubling’ that results from the loss of
myostatin in mice, cattle and humans (Lee, 2004; Tobin and Celeste,
2005). These findings underscore the importance of miRNA-
mediated regulation in diverse muscle biological processes and
disease status.
miRNAs and cardiac hypertrophy
One of the major responses of the heart to biomechanical stress and
pathological stimuli is to undergo extensive cardiac remodeling,
known as cardiac hypertrophy, which is anatomically defined as an
increase in the thickness of the cardiac ventricular wall, owing to
enlargement of myocyte size and/or increased fibrosis (Ahmad et al.,
2005). Cardiac hypertrophy is initially an adaptive response to
maintain cardiac output; however, prolonged hypertrophic growth
is associated with adverse consequences that might lead to heart
failure and sudden death. Myocardial stiffness – which is associated
with myocardial fibrosis – changes in relaxation and contractile
properties, and alterations of cardiac cellularity, including
perivascular inflammation, are all associated with prolonged
hypertrophy (Berk et al., 2007). Cardiac hypertrophy is also
accompanied by reactivation of a set of cardiac fetal genes,
including those that encode atrial natriuretic peptide (ANP; also
known as ANF), B-type natriuretic peptide (BNP), βMHC and
others, suggesting that molecular events controlling heart
development are redeployed to regulate hypertrophic growth
(McKinsey and Olson, 2005).
In addition to their distinct roles in normal heart development,
miRNAs also have significant functions in neonatal and adult hearts
under both physiological and pathological conditions (Callis and
Wang, 2008; van Rooij and Olson, 2007; Zhao and Srivastava, 2007)
(Fig. 4). Recently, miRNA microarray analyses were performed to
examine miRNA expression profiles in hypertrophic or failing hearts
and revealed a collection of miRNAs that are dysregulated under
those pathological conditions (Cheng et al., 2007; Sayed et al., 2007;
Tatsuguchi et al., 2007; Thum et al., 2007; van Rooij et al., 2006).
Furthermore, functional analyses using both gain- and loss-of-
function approaches in mice began to establish the roles of miRNAs
in cardiac hypertrophy.
miR-195 is upregulated during cardiac hypertrophy in both
human and mouse hearts, and is sufficient to induce hypertrophic
growth in cultured rat cardiomyocytes. Cardiac-specific
overexpression of miR-195 induced hypertrophy within several
weeks after birth. Continued miR-195 overproduction led to dilated
cardiomyopathy and heart failure in young mice (van Rooij et al.,
2006). Although the mechanisms that underlie the function of 
miR-195 are not yet clear owing to the lack of target verification,
these studies suggest that miR-195 can actively contribute to the
progression of cardiac disease.
miR-21 is also upregulated in response to agonist-induced
cardiac hypertrophy in cell-culture experiments and in pressure-
overload-induced hypertrophy in vivo (Cheng et al., 2007;
Tatsuguchi et al., 2007; van Rooij et al., 2006). However, the
defined function of miR-21 remains elusive. Inhibition of miR-21
using antisense oligonucleotides suppressed agonist-induced
hypertrophic growth in primary cardiomyocytes (Cheng et al.,
2007), whereas inhibition of miR-21 using locked nucleic-acid-
modified miR-21 antisense oligonucleotides stimulated
hypertrophic growth in vitro (Tatsuguchi et al., 2007). The basis
for these differences is unclear, and further genetic studies and
delineation of the underlying molecular mechanisms that are
modulated by miR-21 in different biological systems are required
to define the function of this miRNA.
Unlike miR-195 and miR-21, the expression of miR-1 and
miR-133 is decreased in diseased human heart, as well as in three
models of cardiac hypertrophy (Care et al., 2007; Sayed et al., 2007;
van Rooij et al., 2006). Overexpression of miR-133 by infecting
both neonatal and adult cardiomyocytes with an adenoviral vector
expressing miR-133 inhibited the hypertrophic response to agonist
stimulation. Conversely, prolonged inhibition of miR-133 in vivo
using chemically modified oligonucleotides antisense to miR-133
produced remarkable hypertrophic growth accompanied by an
induction of fetal gene expression (Care et al., 2007). These studies
indicated that miR-133 has an active role in the inhibition of cardiac
hypertrophy. Although miR-1 also inhibited the hypertrophic growth
of cardiomyocytes in vitro (Sayed et al., 2007), additional genetic
studies are required to confirm the regulatory roles of miR-1 in
cardiac hypertrophy in vivo. Both miR-1 and miR-133 are proposed
to regulate the expression of growth-related genes (Care et al., 2007;
Sayed et al., 2007), indicating that these two miRNAs might act as
growth repressors that are relieved during cardiac hypertrophy.
Further validation of miR-1 and miR-133 targets and the molecular
pathways involved are worthy of pursuit.
miR-208a is expressed specifically in the heart and was deleted
recently from the mouse genome by van Rooij and colleagues
(van Rooij et al., 2007). miR-208a-null mice were viable and
appeared to be normal without any apparent developmental
defects. However, microarray analyses of hearts from wild-type
and mutant mice at 2 months of age revealed statistically
significant upregulated expression of numerous skeletal-muscle
contractile-protein genes, which are normally not expressed in
the heart. Moreover, miR-208a-null animals exhibited a
slight reduction in contractility at 2 months of age and a continued
reduction in cardiac function in later life. These studies suggest
that miR-208a normally maintains the cardiomyocyte contractile
phenotype by repressing the expression of skeletal-muscle genes
in the heart. The remarkable function of miR-208a is revealed by
the aberrant hypertrophic response of miR-208a-null animals.
miR-208a-null mice failed to develop hypertrophy of
cardiomyocytes or fibrosis and were unable to induce fetal βMHC
gene expression in response to constitutively activated calcineurin
signaling or cardiac-pressure-overload-induced stress. miR-208a
is suggested to regulate stress-dependent cardiac growth and gene
expression through, at least in part, the repression of thyroid












thyroid-hormone nuclear receptor. Collectively, miR-208a is
important for the heart stress response but is not crucial for normal
heart development, implying that miR-208a could be an attractive
therapeutic target for βMHC-associated cardiac disorders.
miRNAs and cardiac electrical conduction
The cardiac electrical-conduction system comprises specialized
myocyte cells and distinct sets of ion channels. Functional defects
in the conduction system can result in arrhythmias that cause sudden
and unexpected death. In addition to their function in cardiac
development (Kwon et al., 2005; Zhao et al., 2007), and myoblast
proliferation and differentiation (Chen et al., 2006), miR-1 and
miR-133 also regulate the expression of cardiac conduction-system
components and are arrhythmogenic (Xiao et al., 2007; Yang et al.,
2007).
miR-1 expression is elevated in human hearts with coronary
artery disease and in infarcted rat hearts. To study the role of miR-1
in cardiac pathogenesis, in vivo gene transfer was used to either
enhance or inhibit the function of miR-1 in normal or infarcted rat
hearts (Yang et al., 2007). The injection of miR-1 into the infarcted
myocardium slowed cardiac conduction and led to arrhythmias,
whereas specific knockdown of miR-1 inhibited arrhythmogenesis
(Yang et al., 2007). These studies suggest that miR-1 is involved
in electrical remodeling and arrhythmias, effects that were mediated,
at least in part, through the repression of the KCNJ2 and GJA1
genes. KCNJ2 encodes Kir2.1, the inward rectifying K+ channel
that is involved in setting and maintaining cardiac resting membrane
potential (Diaz et al., 2004), whereas GJA1 encodes Cx43, the main
cardiac gap-junction channel protein, comprising the hemichannels
that are responsible for intercellular conductance in the ventricle
(Jongsma and Wilders, 2000). 
miR-133 has a role in cardiac conductance abnormalities through
the repression of ether-a-go-go-related gene (ERG; also known as
KNCH), which encodes a cardiac K+ channel protein that is
important for myocyte repolarization and is associated with
congenital arrhythmias (Xiao et al., 2007). miR-133 levels were
found to be elevated in the heart in a rabbit model of diabetes, and
this elevation occurred concurrently with lower ERG protein levels
but without a reduction in ERG mRNA levels (Xiao et al., 2007).
Furthermore, the introduction of miR-133 into isolated
cardiomyocytes reduced ERG expression post-transcriptionally
and, accordingly, delayed myocyte repolarization. Together,
increasing evidence has established miRNAs as a novel class of
key regulators of heart development and cardiac function.
miRNAs as novel therapeutic targets
The crucial and widespread roles of miRNAs in cardiac- and
skeletal-muscle development and function raise interesting prospects
for therapeutically exploiting miRNAs in a variety of muscle
diseases. Several characteristics of miRNAs make them unique for
clinical application. First, miRNAs are quite stable and technologies
exist to precisely examine the expression profiles of hundreds of
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Fig. 4. Roles of miRNAs in heart development and function. Diagrams show some of the known roles of muscle-specific miRNAs in heart development and
function. Cardiac-specific deletion of Dicer, a ribonuclease III enzyme that is responsible for miRNA maturation, causes dilated cardiomyopathy and a defect in
cardiac contractility. miR-1 contributes to numerous heart abnormalities, including arrhythmias, myocyte proliferation and cardiac hyperplasia, ventricular
septation defects, and cardiac hypertrophy, whereas miR-133 is associated with arrhythmias and cardiac hypertrophy. In addition, miR-195, mir-208a and miR-21
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miRNAs simultaneously (Bartel, 2004; Thomson et al., 2004),
making miRNAs promising potential biomarkers or diagnostic
indicators of muscle disorders. In fact, it has been reported that
specific miRNA expression patterns are correlated with muscular
dystrophies and other myopathies (Eisenberg et al., 2007). In
addition, distinct miRNA expression signatures have been
implicated in tumors of different types and origins (Garzon and
Croce, 2008; Stahlhut Espinosa and Slack, 2006). Second, miRNAs
are relatively small molecules, making their in vivo delivery
feasible. This is particularly true when additional modifications,
such as cholesterol modification, have been developed to help them
transit across the cell membrane (Krutzfeldt et al., 2007; Krutzfeldt
et al., 2005).
Individual miRNAs are predicted to have multiple mRNA targets
and, most importantly, many of these miRNA regulatory
targets seem to work in concert to control a common pathway and/or
biological function (Esau et al., 2006; Leung and Sharp, 2007). This
unique feature of miRNAs is likely to make them efficient tools
for targeting a particular disease pathway or process. A notable
example is the studies from miR-208a-knockout mice (van Rooij
et al., 2007). These mice exhibited diminished hypertrophy, fibrosis
and fetal gene activation in response to pathological stress, indicating
that therapeutic suppression of miR-208a might restrain
hypertrophic growth after acute or chronic stress. It is interesting
to note that miR-133 represses cardiac hypertrophy (Care et al.,
2007), raising the possibility that the introduction of synthetic
miR-133 into a patient could control pathological hypertrophy.
However, further studies also showed that elevated expression of
miR-133 induces arrhythmias (Xiao et al., 2007), raising concern
about the application of miR-133 in cardiac hypertrophy.
Chemically modified oligonucleotides can be used to either
inhibit a specific miRNA or to disrupt the binding between an
miRNA and its cognate targets. A promising approach in this regard
is to use chemically modified RNA oligonucleotides, named
antagomirs, which form complementary base pairs with miRNA
and effectively inactivate miRNA function in animals in vivo
(Krutzfeldt et al., 2007; Krutzfeldt et al., 2005). Recently, using the
same principle, locked-nucleic-acid-modified oligonucleotide
(LNA-antimiR) was demonstrated to effectively antagonize
miRNAs in non-human primates (Elmen et al., 2008). With the
development of new approaches to inactivate disease-associated
miRNAs, it is important to bear in mind that manipulating miRNA
function could also generate tremendous ‘off-target’ effects. Clearly,
caution is warranted and further studies are required that are directed
at understanding the pathways regulated by miRNAs before clinical
treatments can be seriously considered.
Future prospects for miRNAs in muscle biology and
muscle disorders
miRNA biology is in its infancy and, as an emerging field, there
are many more questions than answers. Current studies, especially
computational analyses, give us a very broad picture in terms of
what miRNAs are likely to be doing. At least one third of human
protein-coding genes are predicted to be regulated by as many as
1000 miRNAs, many of which are uncharacterized in terms of their
expression pattern, function and regulatory targets. Given the vast
number of miRNAs and the diverse functions in different biological
processes observed in the relatively small number of miRNAs
studied thus far, it is apparent that many new and unanticipated
functions of miRNAs in normal muscle development, function and
disorders are awaiting discovery. Considering both that many
miRNAs fine-tune gene-expression programs and the intrinsic
complexity of miRNA functional models, it will take many years
and considerable effort to determine the specificity of miRNA-
mediated gene regulation at whole-organism levels. miRNAs
certainly present a major challenge for the future.
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